[PRNewswire] Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial 2020-09-24 00:27:23

of a single vaccine dose versus placebo in preventing COVID-19. Johnson & Johnson has continued the scaling up of its manufacturing capacity and remains on track to meet its goal of providing one billion doses of a vaccine each year. The Company is committed to bringing an affordable vaccine to the...

• 뉴스 > 정치·사회·국제
• 바로가기
• #Johnson

[PRNewswire] INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with 2020-07-31 09:37:41

single vaccination, with protective neutralizing antibodies and T cells lasting in their blood more than four months after the initial dose. The antibody levels were similar to or greater than those seen in patients who have recovered from COVID-19, the infection caused by SARS-CoV-2, and the T cell...

• 뉴스 > 정치·사회·국제
• 바로가기
• #INOVIOs COVID19

[PRNewswire] Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate 2020-07-30 19:41:03

clinical trial of the single vaccine dose versus placebo in September, pending the interim data of the Phase 1 and 2 trials and approval of regulators. Simultaneously, the Company also is planning to start a parallel Phase 3 clinical trial of a two-dose regimen versus placebo. The Company also will...

• 뉴스 > 정치·사회·국제
• 바로가기
• #Single Dose

[PRNewswire] TWi Biotechnology Receives Canada Health Approval for AC-1101 2020-05-07 16:12:23

an open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 from repeated topical applications of AC-1101 gel to single oral administration of its oral reference product in healthy adult volunteers in Canada and is expected to be completed at the end of 2020. AC-1101 is a...

• 뉴스 > 정치·사회·국제
• 바로가기
• #TWi Biotechnology

[PRNewswire] INOVIO and GeneOne Life Science Report Positive Phase 1/2a 2020-04-29 09:45:30

2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate. Dr. Jerome Kim, Director General of IVI, said, "IVI is pleased...

• 뉴스 > 정치·사회·국제
• 바로가기
• #INOVIO and

[PRNewswire] 머크, 바이러스 벡터 및 유전자 치료제의 상업 제조 능력 확대 2020-04-22 09:51:19

a single dose may cure the disease. Viral vectors are often called the most complex therapeutic manufactured today. The gene therapy market, which accounted for $1 billion in 2018, is expected to reach $10 billion by 2026, according to a recent Biotech Forecasts global market analysis and industry...

• 뉴스 > 정치·사회·국제
• 바로가기
• #머크 바이러스 #유전자 #머크 #치료제 #바이러스 #제조 #동사 #사업 #벡터 #생산 #설비

[PRNewswire] Genome & Company announces a clinical trial collaboration and 2020-01-14 09:06:44

single strain bacteria isolated from gut of healthy human volunteers that has been shown to activate dendritic cells, macrophages and T cell response. In preclinical studies, GEN-001 has shown optimal safety margin and synergistic effects in combination with immune checkpoint inhibitors by enhancing...

• 뉴스 > 정치·사회·국제
• 바로가기
• #Genome #연합뉴스

[PRNewswire] Helsinn and Mundipharma China Pharmaceutical jointly announce 2019-09-25 16:37:09

of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo(R) that targets two CINV critical pathways in a single dose will help patients and their families also in China "We are also very pleased to be working in partnership with Mundipharma Pharmaceutical....

• 뉴스 > 정치·사회·국제
• 바로가기
• #Helsinn and #연합뉴스